FDA Class I Recall: China-Based EnShiShiXiangNiShangMaoYouXianGongSi's Adulterated Supplement via Amazon
EnShiShiXiangNiShangMaoYouXianGongSi initiated a Class I recall for its 'ENDURANCE BOOST WITH HORNY GOAT WEED' supplement, distributed nationwide via Amazon. The product, originating from China, was found to be tainted with undeclared Sildenafil and Propoxyphenylsildenafil, marketed without FDA approval. This event underscores critical supply chain risks in direct-to-consumer channels, demanding heightened due diligence from procurement and regulatory teams to prevent adulterated products.
FDA Class I Recall: Unapproved Drug Status and Adulteration with Sildenafil
EnShiShiXiangNiShangMaoYouXianGongSi, a firm based in China, has initiated a voluntary, firm-initiated Class I recall for its product marketed as 'ENDURANCE BOOST WITH HORNY GOAT WEED'. This critical action, designated recall number D-0453-2025, commenced on May 6, 2025, and remains ongoing. The primary regulatory violations identified by the FDA are severe: the product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA), and it was found to be adulterated with undeclared active pharmaceutical ingredients (APIs). Specifically, laboratory analysis confirmed the presence of Sildenafil and Propoxyphenylsildenafil, a known sildenafil analogue. For procurement directors and regulatory affairs heads, this incident highlights the paramount importance of verifying the regulatory status of all products, particularly those making health-related claims. The presence of undeclared APIs transforms a purported dietary supplement into an unapproved drug, triggering the highest level of recall classification due to the potential for serious adverse health consequences, including life-threatening interactions with other medications like nitrates. This event underscores the FDA's stringent enforcement against products that bypass established drug approval pathways, posing significant risks to public health and market integrity.
EnShiShiXiangNiShangMaoYouXianGongSi's Product Profile and Market Reach
The recalled product, identified as 'ENDURANCE BOOST WITH HORNY GOAT WEED, 500mg, 20 capsules per carton', is branded as a VEPEMVA Nutrition Supplement with UPC X004BB9Z8N. The specific lot affected is 250214PRO, with an expiration date of February 14, 2027. A total of 600, 20-count cartons were distributed nationwide across the United States. Crucially, the distribution channel for this product was the Amazon platform, indicating a direct-to-consumer model that bypasses many traditional pharmaceutical and nutraceutical supply chain checkpoints. The manufacturer, EnShiShiXiangNiShangMaoYouXianGongSi, operates from an unknown facility location in China. For business development executives, this case illustrates the broad reach of e-commerce platforms and the inherent challenges in monitoring products originating from regions with less transparent regulatory oversight. Supply chain VPs must recognize that direct online sales can introduce unvetted products into the market, creating significant exposure for consumers and potential reputational damage for platforms facilitating such sales. The lack of specific facility details for the Chinese manufacturer further complicates traceability and accountability, presenting a formidable barrier to comprehensive supply chain risk assessment.
Critical Supply Chain Vulnerabilities: E-commerce and Foreign Sourcing
This Class I recall by EnShiShiXiangNiShangMaoYouXianGongSi exposes critical vulnerabilities within global supply chains, particularly concerning products sourced from foreign entities and distributed through e-commerce platforms. The absence of an approved NDA/ANDA, combined with the adulteration by Sildenafil and its analogue, highlights a severe breakdown in quality control and regulatory compliance at the source. The direct-to-consumer distribution model via Amazon means these unapproved, potentially dangerous drug products reached consumers without the rigorous scrutiny typically applied to pharmaceutical imports. For procurement directors, this underscores the urgent need to extend due diligence beyond direct suppliers to encompass all points of origin, especially for products marketed as supplements from countries like China where regulatory enforcement can vary. The health risks associated with undeclared Sildenafil are substantial, including severe hypotension, myocardial infarction, and stroke, particularly for individuals with cardiovascular conditions or those concomitantly using nitrate medications. Supply chain VPs must implement robust strategies to identify and mitigate risks from opaque foreign suppliers, recognizing that the convenience of e-commerce can inadvertently facilitate the entry of non-compliant and hazardous products into the market, circumventing established safety nets.
Regulatory Landscape: Heightened Scrutiny on Dietary Supplements
The FDA's action against EnShiShiXiangNiShangMaoYouXianGongSi reinforces the agency's unyielding focus on eliminating adulterated and misbranded products from the dietary supplement market. Products containing undeclared pharmaceutical ingredients like Sildenafil are unequivocally classified as unapproved new drugs, not dietary supplements, and are subject to stringent regulatory action. This recall serves as a clear signal to the global chemical and life sciences industry that the FDA maintains a zero-tolerance policy for products that masquerade as supplements while containing potent, undeclared APIs. Regulatory affairs heads must interpret this event as a call to action, demanding a comprehensive review of their own product portfolios, especially those in the performance enhancement or 'natural' health categories. The distinction between a dietary supplement, which is regulated under the Dietary Supplement Health and Education Act (DSHEA), and a drug, which requires an NDA or ANDA, is fundamental. Any product making drug-like claims or containing drug-like ingredients without FDA approval faces immediate and severe regulatory consequences, including recalls, import alerts, and potential legal penalties. Companies must ensure their product formulations, labeling, and marketing claims strictly adhere to the appropriate regulatory framework to avoid similar enforcement actions.
Proactive Risk Mitigation: Enhanced Due Diligence and Quality Assurance Imperatives
In light of the EnShiShiXiangNiShangMaoYouXianGongSi recall, senior decision-makers must prioritize proactive risk mitigation strategies to safeguard their businesses and consumers. For procurement teams, this necessitates implementing rigorous third-party testing protocols for all incoming raw materials and finished products, specifically screening for undeclared APIs, even from seemingly reputable suppliers or those distributing via major online platforms. Comprehensive supplier audits, particularly for overseas manufacturers, must be conducted to verify their quality management systems, manufacturing processes, and adherence to Good Manufacturing Practices (GMPs). Supply chain VPs should invest in advanced analytical capabilities and partner with accredited contract testing organizations to ensure product integrity. Business development executives exploring new markets or product lines, especially in the nutraceutical space, must ensure that product development and marketing claims are fully compliant with FDA regulations, avoiding any ingredients or assertions that could lead to an unapproved drug classification. This incident serves as a stark reminder that robust quality assurance, transparent supply chains, and unwavering regulatory compliance are not merely best practices but essential safeguards against severe financial, reputational, and legal repercussions in the global chemical and life sciences industry.